Targeting drugs across the blood brain barrier (BBB) is dependent on efficient delivery systems [1–4]. Certain drugs such as shortpeptide sequences show promising, medically relevant, biologicalresponses for the treatment of Alzheimer’s disease (AD) but theyhave limited ability of reaching the brain [5–7].